If you're at a pre-commercial biotech, standing up a formal S&OP process can feel like something you'll worry about after approval. But by the time you think you need it, you're already behind.

There's a moment in every biotech's journey when the supply chain shifts from supporting clinical development to preparing for commercial reality — and almost everything about how the organization operates needs to change with it.

Many difficult CMO relationships were set up to fail from the start — not because the CMO was bad, but because the selection process was flawed. Here's what actually matters when choosing a manufacturing partner.

The TSA shutdown is grinding airports to a halt. If you're running a biotech supply chain with the same kind of single-point-of-failure risk, the question isn't whether you'll face your own version of this crisis — it's when.

Across the biotech industry, sponsor-CMO friction is one of the most persistent operational challenges. When your CMO underperforms, it's your patients, your timelines, and your regulatory standing on the line. Here's how to have the hard conversation — without torching the relationship.

Most early-stage biotech companies wait too long to build a real supply chain function — and the ones that don't often build the wrong things first. Here's what the right sequencing looks like and the three decisions that matter most in year one.